Fundraise

India's Anondita Medicare raises $9.66M in rights issue as capacity hits 869M

What's the deal? Anondita MedicareDealroom has a profile for this one. Try Dealroom →, a Noida-based condom maker, completed a US$12.4M post-IPO equity raise through a rights issue priced at US$12.9 per share. The company says the proceeds will fund female-condom manufacturing, infrastructure, working capital, and domestic and international expansion.

Why now? The raise follows a sharp capacity expansion: Anondita added 307 million male-condom pieces on February 23, 2026, lifting installed annual capacity from 562 million to 869 million pieces. Management now expects about 1.1 billion pieces of annual male-condom capacity once four new lines enter commercial production.

What's the endgame? Anondita is moving into female latex and non-latex condoms, a category it describes as underpenetrated with institutional and global procurement potential. It targets two female-latex lines by end-December and two non-latex lines in commercial production during FY27. Management estimates global commercial and public-procurement demand for female condoms at 700 million to 1.5 billion pieces annually.

The round follows a US$9.44M IPO in 2025. Shares listed on NSE Emerge in September 2025 and are up more than 600% since, closing at US$14.1 on November 16, 2026.

Show me the numbers: For the first half of FY27, revenue rose 35.9% year on year to US$9.99M and net profit climbed 69% to US$2.99M. Management committed to FY27 revenue of US$32.6M-US$34M and aims to reach the US$135.8M mark by FY29.

What could go wrong? Installed capacity does not guarantee demand or utilisation. Borrowings rose to US$4.56M, debtor days stretched to 138 in FY26, and the company has not disclosed that it has won a UNFPA, Global Fund, or government female-condom contract — making returns on the new capacity the key test.

The signal: Anondita's raise ties financing directly to a scale-up, betting that institutional and export channels — from government health programmes to African shipments — can absorb a rapidly growing output. Execution, not ambition, will decide whether the capacity pays off.

Read more: multibagg.ai

Image credit: Generated with Gemini

More top stories